Filed in archive
Corporate and Industrial News
, Drugs, Vaccines and Therapeutics
by ruth on October 17, 2006

The value of all payments to Glenmark could total up to EUR 190 million, including a EUR 25 million up-front payment and various milestone payments upon successful development and launch of Mono-therapy and combination products based on GRC 8200. Upon commercial launch, Glenmark will supply the active ingredient to Merck and will receive royalties on net sales of the product.
Glenmark retains marketing rights for India while Merck KGaA gains North America, Europe and Japan markets.
Source: Merck
Tags:
diabetes
type2+diabetes
biotech
pharmaceutical
insulin
glenmark
glenmark+pharmaceuticals
type+diabet
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/39469
Mr Wong
Vote for Merck KGaA Licenses Glenmark Pharmaceuticals' DPPIV Inhibitor for Type 2 Diabetes:
|
Rating: 9.75 out of 4 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







